journal article·2016-02

Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass

He Yuan, Li-na Niu, Kai Jiao, Dan-dan Pei, Chandrani Pramanik, Ji-yao Li, Regina Messer, Satish Kumar, David H. Pashley, Franklin R. Tay

Acta Biomaterialia· Volume 31
Publisher page

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious skeletal complication associated with the long-term oral or intravenous use of nitrogen-containing bisphosphonates (N-BPs). Here, we investigated the effects of an ionic cocktail prepared from water-soluble microfibrous borate glass on neutralizing the inhibitory effects of two heterocyclic N-BPs, risedronate or zoledronic acid, on osteoclastogenesis, apoptosis of differentiated osteoclasts and osteoclast function. Cell growth and proliferation assays were first performed on RAW 264.7 cells to optimize the concentrations of the ionic cocktail and N-BPs to be used for static cell culture. The pre-osteoclasts were then stimulated with RANKL to differentiate into osteoclasts. The effects of the ionic cocktail and N-BPs on osteoclast differentiation, apoptosis and function were subsequently examined using 3 series of experiments conducted at the gene, protein, morphological and functional levels. After concentration optimization, the ionic cocktail was found to partially reverse N-BP-induced inhibition of osteoclastogenesis, stimulation of osteoclasts apoptosis and reduction of osteoclast resorptive activity. Ultrastructural examination of osteoclasts that had been exposed to either N-BP identified classical features of late apoptosis and secondary necrosis, while osteoclasts exposed simultaneously to the concentration-optimized ionic cocktail and N-BPs exhibited only signs of early apoptosis that were possibly reversible. Taken together, the results of the 4 series of experiments indicate that the ionic cocktail produced from dissolution of borate glass dressings has the potential to rescue the adverse effects of heterocyclic N-BPs on osteoclast differentiation and function. These results warrant further confirmation using dynamic cell culture and small animal BRONJ models. Statement of significance Long-term oral and intravenous use of nitrogen-containing bisphosphonates (N-BPs) may result in bisphosphonate-related osteonecrosis of the jaw (BRONJ) due to the suppression of normal bone turnover. There is no effective treatment for such a complication to date. This work reported the use of an ionic cocktail derived from water-soluble microfibrous borate glass to revert heterocyclic N-BP-induced inhibition of osteoclastogenesis, stimulation of osteoclasts apoptosis and reduction of osteoclasts resorption in static cell culture condition. This ionic cocktail may have the potential to be further developed into a new adjunctive treatment for BRONJ.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone health and treatments · Bone Tissue Engineering Materials · Bone Metabolism and Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Osteoclast differentiation and activation10.1038/nature01658 ↗
2. Bisphosphonates: the first 40 years10.1016/j.bone.2011.04.022 ↗
3. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite10.1016/S0026-895X(24)12222-5 ↗
4. Biochemical and molecular mechanisms of action of bisphosphonates10.1016/j.bone.2010.11.008 ↗
5. Infection and medication-related osteonecrosis of the Jaw10.1177/0022034515572021 ↗
6. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management10.1016/j.tripleo.2006.06.004 ↗
7. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study10.1016/j.ijom.2012.06.020 ↗
8. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges10.1007/s00198-012-2042-6 ↗
9. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus10.1002/jbmr.2405 ↗
10. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions10.1007/s00774-008-0018-6 ↗
11. Bioactive glass in tissue engineering10.1016/j.actbio.2011.03.016 ↗
12. The effect of ionic products from bioactive glass dissolution on osteoblast proliferation and collagen production10.1016/j.biomaterials.2003.09.086 ↗
13. Silicate, borosilicate, and borate bioactive glass scaffolds with controllable degradation rate for bone tissue engineering applications. II. In vitro and in vivo biological evaluation10.1002/jbm.a.32823 ↗
14. Microfibrous borate bioactive glass dressing sequesters bone-bound bisphosphonate in the presence of simulated body fluid10.1039/C4TB02035A ↗
15. A mechanistic study of the interaction of water-soluble borate glass with apatite-bound heterocyclic nitrogen-containing bisphosphonates10.1016/j.actbio.2015.12.008 ↗
16. Paracelsus, Haber and Arndt10.1016/S0300-483X(00)00447-9 ↗
17. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro10.1016/S8756-3282(01)00412-4 ↗
18. Neuropeptide FF attenuates RANKL-induced differentiation of macrophage-like cells into osteoclast-like cells10.1016/j.archoralbio.2014.11.005 ↗
19. Apoptosis: a review of programmed cell death10.1080/01926230701320337 ↗
20. Conversion of borate glass to hydroxyapatite and its effect on proliferation of MC3T3-E1 cells10.1002/jbm.a.31679 ↗
21. NFATc1: functions in osteoclasts10.1016/j.biocel.2009.12.018 ↗
22. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium10.1093/clinchem/46.11.1751 ↗
23. Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development10.1359/jbmr.1998.13.4.673 ↗
24. The effect of matrix metalloproteinase-9 on the differentiation into osteoclast cells on RAW264 cells10.1016/j.odw.2007.09.003 ↗
25. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells10.1007/s00774-006-0697-9 ↗
26. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss10.1248/bpb.32.1193 ↗
27. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 210.1016/j.archoralbio.2014.09.012 ↗
28. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis10.1007/s00210-010-0596-4 ↗
29. β-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species10.1152/ajpendo.00191.2012 ↗
30. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases10.1007/s00774-015-0656-4 ↗
31. Reactive oxygen species mediate RANK signaling in osteoclasts10.1016/j.yexcr.2004.07.035 ↗
32. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation10.1182/blood-2004-09-3662 ↗
33. Osteoclast apoptosis: the role of Fas in vivo and in vitro10.1210/en.2003-0296 ↗
34. Caspase-8 regulation of TRAIL-mediated cell death
35. Revival of apoptotic cells that display early-stage dynamic membrane blebbing10.1016/j.febslet.2007.08.033 ↗
36. Reversibility of apoptosis in cancer cells10.1038/sj.bjc.6604802 ↗
37. Cell morphological changes combined with biochemical assays for assessment of apoptosis and apoptosis reversal
38. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors10.1016/j.bone.2014.07.003 ↗
39. Early stages of p53-induced apoptosis are reversible10.1038/sj.cdd.4400786 ↗
40. P53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints10.1158/1541-7786.MCR-14-0177 ↗
41. Cancer. p53, guardian of the genome10.1038/358015a0 ↗
42. Systematic genome-wide screens of gene function10.1038/nrg1248 ↗
43. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function10.1007/s00223-002-2017-2 ↗
44. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition10.1177/0022034514564187 ↗